• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511

Introduction to 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid (CAS No. 1190319-18-6)

1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid, with the chemical identifier CAS No. 1190319-18-6, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the pyrrolopyridine class, a structural motif that is widely recognized for its biological activity and potential therapeutic applications. The unique arrangement of nitrogen atoms in its ring system imparts distinct electronic and steric properties, making it a valuable scaffold for drug discovery and development.

The pyrrolo[3,2-b]pyridine core is a fused bicyclic system consisting of a pyrrole ring and a pyridine ring, connected at the 3-position of pyrrole and the 2-position of pyridine. This structural configuration creates a rigid framework with potential for diverse interactions with biological targets. The 7-carboxylic acid substituent at the 7-position of the pyrrolopyridine ring introduces a polar, acidic functional group that can enhance solubility and binding affinity in biological systems. This combination of features makes 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid a promising candidate for further exploration in medicinal chemistry.

In recent years, there has been growing interest in heterocyclic compounds as pharmacophores due to their prevalence in bioactive natural products and synthetic drugs. 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid is no exception, and its potential has been recognized by researchers working on various therapeutic areas. One of the most compelling aspects of this compound is its ability to modulate biological pathways associated with inflammation, cancer, and neurodegenerative diseases. The presence of both nitrogen and oxygen-containing heterocycles in its structure allows for multiple interaction points with biological targets, including enzymes and receptors.

Recent studies have highlighted the significance of 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid in the development of novel therapeutic agents. For instance, researchers have demonstrated its potential as an inhibitor of kinases, which are enzymes involved in cell signaling pathways that are often dysregulated in cancer. The carboxylic acid group at the 7-position serves as a key pharmacophore for binding to active sites on kinases, while the pyrrolopyridine core provides additional interactions through hydrogen bonding and hydrophobic effects. These findings suggest that 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid could be a valuable starting point for designing kinase inhibitors with improved efficacy and selectivity.

Another area where 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid has shown promise is in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The compound's ability to cross the blood-brain barrier and interact with neuronal receptors has been explored in preclinical studies. Specifically, derivatives of 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid have been found to exhibit neuroprotective effects by modulating neurotransmitter systems and reducing oxidative stress. These findings are particularly exciting given the unmet medical needs associated with neurodegenerative diseases.

The synthesis of 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid has also been a subject of interest in synthetic chemistry. Researchers have developed various synthetic routes to construct this heterocyclic system efficiently and in high yield. One common approach involves cyclization reactions between appropriately substituted pyrroles and pyridines under controlled conditions. These synthetic strategies have enabled access to a library of derivatives that can be screened for biological activity. The ability to modify different positions on the 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid scaffold allows for fine-tuning of its pharmacological properties, making it an attractive scaffold for drug development.

The pharmacokinetic properties of 1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid are also important considerations in drug design. Studies have shown that this compound exhibits reasonable oral bioavailability and metabolic stability in preclinical models. These characteristics are crucial for ensuring that the drug reaches its target site at effective concentrations and remains stable within the body long enough to exert its therapeutic effects. Additionally, the compound's solubility profile has been optimized through structural modifications to enhance its bioavailability.

In conclusion,1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid (CAS No. 1190319-18-6) is a versatile heterocyclic compound with significant potential in pharmaceutical research. Its unique structural features make it an excellent scaffold for developing novel therapeutic agents targeting various diseases. Recent studies have highlighted its role in modulating kinases and neurotransmitter systems, providing a strong rationale for further exploration in drug discovery programs. With ongoing advancements in synthetic chemistry and pharmacology,1H-Pyrrolo[3,2-b]pyridine-7-carboxylic acid is poised to play a crucial role in the development of next-generation pharmaceuticals.

• 860363-17-3(1H-Pyrrolo[3,2-b]pyridine-3-carboxylic acid hydrochloride)
• 952800-39-4(Methyl 1H-pyrrolo[3,2-B]pyridine-3-carboxylate)
• 112766-32-2(1H-Pyrrolo[3,2-b]pyridine-6-carboxylic acid)
• 1190315-00-4(6-(Methoxycarbonyl)-1H-pyrrolo[3,2-b]pyridine-3-carboxylic acid)
• 1227270-42-9(6-Phenyl-3-(4-azaindole)carboxylic Acid)
• 1190315-88-8(6-Cyano-4-azaindole-3-carboxylic Acid)
• 860496-20-4(1H-Pyrrolo[3,2-b]pyridine-3-carboxylic acid)
• 369652-76-6(pyrazino[2,3-a]phenazine-11-carboxylic acid)
• 90418-64-7(1,5-Naphthyridine-3-carboxylic acid)
• 79426-14-5(1,5-Naphthyridine-4-carboxylic acid)